Nkarta, Inc. 8K

Nkarta, Inc. announced second quarter 2026 financial results and provided updates on the ongoing NKX019 Ntrust-1 and Ntrust-2 autoimmune trials, confirming continued enrollment, outpatient dosing expansion, and a cash runway projected into 2029.

Nkarta, Inc. reported its unaudited financial results for the quarter ended June 30, 2026 and provided corporate updates on its NKX019 autoimmune program, highlighting continued patient enrollment at the 4 billion cell dose level in the Ntrust-1 and Ntrust-2 clinical trials, initiation of outpatient dosing across a growing network of community-based sites with the possibility of re-dosing, and plans to present initial clinical data from these studies at a medical conference in 2026. The company disclosed a cash, cash equivalents, restricted cash and marketable securities balance of $243.2 million as of June 30, 2026, which it expects will fund its current operating plan into 2029, and reported second quarter 2026 research and development expenses of $29.0 million, general and administrative expenses of $14.1 million, and a net loss of $40.4 million, or $0.54 per share, including $11.8 million of non-cash charges primarily related to share-based compensation, depreciation, and asset impairments.

Filing Facts

CIK

1787400

Ticker

-

Form

8K

Source Type

sec

Accession

0001193125-26-342402

Alert Tier

5